Trial Profile

An Open-Label, Phase 1/2A Dose Escalation Study of Safety and Efficacy of NEO100 in Recurrent or Progressive Grade III or Grade IV Gliomas With IDH1 Mutation

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 21 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Perillyl alcohol (Primary)
Indications Astrocytoma; Glioblastoma; Glioma
Focus Adverse reactions; Therapeutic Use
Sponsors NEONC Technologies

Most Recent Events

16 Sep 2026 Results presented in the NeOnc Technologies media release
14 Sep 2026 Planned End Date changed from 1 Aug 2026 to 1 Dec 2026.
14 Sep 2026 Planned primary completion date changed from 30 Jul 2026 to 30 Nov 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com